Search

Displaying results 3481 - 3490 of 6076 in total
  1. Drug

    Losmapimod

    go.drugbank.com/drugs/DB12270
    Investigational

    Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.

  2. Drug

    Salvinorin A

    go.drugbank.com/drugs/DB12327
    Investigational

    Salvinorin A has been investigated for the basic science of Pharmaceutical Preparations.

  3. Drug

    Urapidil

    go.drugbank.com/drugs/DB12661
    Investigational

    Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

  4. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for

  5. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  6. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  7. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this … Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405].

  8. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    However, there currently are no clinical indications for preferential use of ridogrel over aspirin. … Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency